(Q43756717)

26 November 2017

In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? (English)

1 reference

26 November 2017

1 reference

Budman DR

1

1 reference

26 November 2017

Calabro A

series ordinal

2

1 reference

26 November 2017

Kreis W

series ordinal

3

1 reference

26 November 2017

1 October 2001

1 reference

26 November 2017

1 reference

26 November 2017

15

1 reference

26 November 2017

10

1 reference

26 November 2017

1517-1520

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402244

26 November 2017

0 references

cites work

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Late cardiotoxicity of anthracyclines in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Reduction of daunomycin toxicity by razoxane

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Dexrazoxane (ICRF-187).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Coincident acute myelogenous leukemia and ischemic heart disease: use of the cardioprotectant dexrazoxane during induction chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402244

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402244

1 reference

Dimensions Publication ID

26 November 2017

0 references

1 reference